Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in Relapsed/Refractory HER2+ B-ALL
NCT00724360Phase 2Terminated
- Sponsor
- CHU de Nantes
- Start
- Nov 2006
- Primary completion
- Jul 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by CHU de Nantes. Started Nov 2006; status: terminated.
02
Drugs
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT00724360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00724360.